Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer
Copyright: © Tsakogiannis et al..
Breast cancer is the most common type of cancer in females and is the leading cause of cancer-associated death among women, worldwide. The present study aimed to measure the serum levels of fatty acid-binding protein 4 (FABP4), retinol binding protein 4 (RBP4) and the MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) complex in women diagnosed with breast cancer. Serum levels of the examined proteins were determined in the peripheral blood of patients via ELISA. Furthermore, whether the concentration of each protein was associated with breast cancer growth, molecular subtype, BMI, postmenopausal status, diabetes and the social background of patients was assessed. Women with invasive breast cancer demonstrated significantly higher levels of FABP4 (P=0.008). Additionally, considerably elevated FABP4 levels were demonstrated specifically in Luminal breast cancer cases (P<0.01). No significant association was recorded between RBP4 and breast cancer development. In addition, significantly lower levels of the MMP-9/NGAL complex were recorded in triple negative/HER-2 cases (P<0.05). BMI values appeared to influence the aforementioned associations, while significantly high serum levels of FABP4 and the MMP-9/NGAL complex were found in postmenopausal patients with breast cancer and a BMI ≥25 kg/m2 (P<0.05). In addition, high levels of FABP4 were significantly associated with breast cancer patients with diabetes (P=0.05). However, no association was identified between RBP4, the MMP-9/NGAL complex and diabetes. In conclusion, FABP4 can be regarded as a biomarker of breast cancer growth, while both FABP4 and the MMP-9/NGAL complex may provide considerable information regarding the development of specific breast cancer subtypes. FABP4 and the MMP-9/NGAL complex may also be able to predict the development of breast cancer in postmenopausal patients with obesity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Oncology letters - 21(2021), 2 vom: 24. Feb., Seite 85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsakogiannis, Dimitris [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 31.12.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/ol.2020.12346 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319406555 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319406555 | ||
| 003 | DE-627 | ||
| 005 | 20231225171359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ol.2020.12346 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319406555 | ||
| 035 | |a (NLM)33376518 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsakogiannis, Dimitris |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Tsakogiannis et al. | ||
| 520 | |a Breast cancer is the most common type of cancer in females and is the leading cause of cancer-associated death among women, worldwide. The present study aimed to measure the serum levels of fatty acid-binding protein 4 (FABP4), retinol binding protein 4 (RBP4) and the MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) complex in women diagnosed with breast cancer. Serum levels of the examined proteins were determined in the peripheral blood of patients via ELISA. Furthermore, whether the concentration of each protein was associated with breast cancer growth, molecular subtype, BMI, postmenopausal status, diabetes and the social background of patients was assessed. Women with invasive breast cancer demonstrated significantly higher levels of FABP4 (P=0.008). Additionally, considerably elevated FABP4 levels were demonstrated specifically in Luminal breast cancer cases (P<0.01). No significant association was recorded between RBP4 and breast cancer development. In addition, significantly lower levels of the MMP-9/NGAL complex were recorded in triple negative/HER-2 cases (P<0.05). BMI values appeared to influence the aforementioned associations, while significantly high serum levels of FABP4 and the MMP-9/NGAL complex were found in postmenopausal patients with breast cancer and a BMI ≥25 kg/m2 (P<0.05). In addition, high levels of FABP4 were significantly associated with breast cancer patients with diabetes (P=0.05). However, no association was identified between RBP4, the MMP-9/NGAL complex and diabetes. In conclusion, FABP4 can be regarded as a biomarker of breast cancer growth, while both FABP4 and the MMP-9/NGAL complex may provide considerable information regarding the development of specific breast cancer subtypes. FABP4 and the MMP-9/NGAL complex may also be able to predict the development of breast cancer in postmenopausal patients with obesity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MMP-9/neutrophil gelatinase-associated lipocalin | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a fatty acid-binding protein 4 | |
| 650 | 4 | |a molecular subtype | |
| 650 | 4 | |a retinol binding protein 4 | |
| 700 | 1 | |a Kalogera, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Zagouri, Flora |e verfasserin |4 aut | |
| 700 | 1 | |a Zografos, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Balalis, Dimitris |e verfasserin |4 aut | |
| 700 | 1 | |a Bletsa, Garyfalia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology letters |d 2010 |g 21(2021), 2 vom: 24. Feb., Seite 85 |w (DE-627)NLM201171317 |x 1792-1082 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:2 |g day:24 |g month:02 |g pages:85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ol.2020.12346 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 2 |b 24 |c 02 |h 85 | ||